Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice
Table 2
Gastrointestinal symptoms at baseline and after 1 year according to randomization group.
Gastrointestinal symptom rating scale, median (IQR)
Baseline
1 year
value
Placebo
PPI
Placebo
PPI
Total score
2.6 (2.4; 2.8)
2.5 (2.3; 2.7)
1.9 (1.7; 2.1)
1.8 (1.7; 2.0)
0.73
Abdominal pain
2.7 (2.4; 3.0)
2.6 (2.4; 2.8)
2.0 (1.8; 2.3)
1.8 (1.6; 2.0)
0.58
Reflux
3.2 (2.8; 3.5)
3.1 (2.7; 3.4)
1.8 (1.6; 2.0)
1.8 (1.6; 2.0)
0.74
Indigestion
3.1 (2.8; 3.3)
3.0 (2.7; 3.2)
2.2 (2.0; 2.5)
2.2 (1.9; 2.4)
0.83
Diarrhea
2.2 (1.9; 2.5)
1.9 (1.6; 2.1)
1.6 (1.4; 1.8)
1.5 (1.3; 1.7)
0.48
Constipation
2.2 (1.9; 2.5)
2.0 (1.7; 2.3)
1.8 (1.5; 2.0)
1.7 (1.5; 2.0)
0.88
Esomeprazole 40 mg. Gastrointestinal symptom rating scale. Range 1–7. Increasing values reflect increasing symptoms. Between group comparison. Difference in GSRS score at entry versus one year. Conditional linear regression adjusted for GP clusters.
